期刊文献+

肺癌中医五型与EGFR相关性研究 被引量:13

下载PDF
导出
摘要 目的:探讨肺癌中医五型与表皮生长因子受体表达之间的相关性。方法:收集资料齐全的120例肺癌患者,按中医辨证分为肺阴亏虚型、气虚亏虚型、痰湿蕴肺型、肾阳虚衰型、肺脾气虚型,分别对其病理标本的蜡块用免疫组化法对表皮生长因子受体(EGFR)的表达进行观察、分析。结果 :肺癌患者中肺阴亏虚型、气虚亏虚型、痰湿蕴肺型、肾阳虚衰型、肺脾气虚型依次增高。肺脾气虚型、肾阳虚衰型与肺阴亏虚型比较有显著差异性(P<0.05)。结论:EGFR表达差异与肺癌不同证型相关,可指导临床的用药。
出处 《辽宁中医药大学学报》 CAS 2012年第11期97-98,共2页 Journal of Liaoning University of Traditional Chinese Medicine
基金 江西省卫生厅中医药科研基金项目(2009A090)
关键词 肺癌 EGFR 相关性
  • 相关文献

参考文献2

二级参考文献23

  • 1Kris MG,Natale RB,Herbst RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer,JAMA,2003,290(16):2149-2158.
  • 2Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.J Clin Oncol,2003,21(12):2237-2246.
  • 3Giaccone G,Herbst RS,Manegold C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer:a Phase III clinical trial-INTACT 1.J CIin Oncol,2004,22(5):777-784.
  • 4Herbst RS,Giaccone G,Schiller JH,et al.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase III trial-INTACT 2.J Clin Oncol,2004,22(5):785-794.
  • 5Thatcher N,Chang A,Parikh P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomised,placebo-controlled,multicenter study(Iressa Survival Evaluation in Lung Cancer).Lancet,2005,366(9496):1527-1537.
  • 6Franklin WA,Veve R,Hitch FR,et al.Epidermal growth factor receptor family in lung cancer and premalignancy.Semin Oncol,2002,29(1 suppl 4):3-14.
  • 7Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med,2004,350(21):2129-2139.
  • 8Bell DW,Lynch TJ,Haserlat SM,et al.Epidermal growth factor receptor mutmions and gene amplification in non-small-cell lung cancer:molecular analysis of the IDEAL/INTACT gefitinib trials.J Clin Oncol,2005,23(31):8081-8092.
  • 9Shepherd FA,Rodrigues Pereira J,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med,2005,353(2):123-132.
  • 10Perez-Soler R,Chachoua A,Hammond LA,et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer.J Clin Oncol,2004,22(16):3238-3247.

共引文献4

同被引文献212

引证文献13

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部